<DrugInformationSummary id="CDR0000743644"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Cabozantinib-s-malate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that supply oxygen and nutrients needed for tumor growth. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. Cabozantinib-s-malate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/cabozantinib-s-malate">Cabozantinib-S-Malate</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000461103">cabozantinib S-malate</TerminologyLink><GlossaryLink ref="CDR0000743915">cabozantinib-s-malate</GlossaryLink><USBrandNames><USBrandName>Cabometyx</USBrandName><USBrandName>Cometriq</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>KA-boh-ZAN-tih-nib ... MA-layt</TermPronunciation><MediaLink ref="CDR0000746310" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000746311" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=CABOZANTINIB&amp;pagesize=20&amp;page=1&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Cabozantinib-S-Malate</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=CABOZANTINIB&amp;pagesize=20&amp;page=1&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Cabozantinib-s-malate
         is approved 
         to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem> <Strong><GlossaryTermRef href="CDR0000806206" dictionary="Cancer.gov" audience="Patient">Differentiated thyroid cancer</GlossaryTermRef></Strong> that has spread. It is used in adults and children aged 12 years and older who cannot receive <GlossaryTermRef href="CDR0000045855" dictionary="Cancer.gov" audience="Patient">radioactive iodine</GlossaryTermRef> and whose cancer got worse after <GlossaryTermRef href="CDR0000044474" dictionary="Cancer.gov" audience="Patient">VEGF</GlossaryTermRef> <GlossaryTermRef href="CDR0000044958" dictionary="Cancer.gov" audience="Patient">receptor</GlossaryTermRef>-<GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">targeted therapy</GlossaryTermRef>. This use is approved for the Cabometyx brand of cabozantinib-s-malate.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">Hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>). It is used in patients who have already been treated with <GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib</GlossaryTermRef>. This use is approved for the Cabometyx brand of cabozantinib-s-malate.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044550" dictionary="Cancer.gov" audience="Patient">Medullary thyroid cancer</GlossaryTermRef></Strong> that has gotten worse and has spread to other parts of the body. This use is approved for the Cometriq brand of cabozantinib-s-malate.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044904" dictionary="Cancer.gov" audience="Patient">Neuroendocrine tumor</GlossaryTermRef></Strong> of the <GlossaryTermRef href="CDR0000046254" dictionary="Cancer.gov" audience="Patient">pancreas</GlossaryTermRef> or another organ that is <GlossaryTermRef href="CDR0000774690" dictionary="Cancer.gov" audience="Patient">well-differentiated</GlossaryTermRef>, has spread, and cannot be removed by surgery. It is used in adults and children aged 12 years and older whose cancer has been treated. This use is approved for the Cabometyx brand of cabozantinib-s-malate.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">Renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>) that is <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef>. It is either used with <GlossaryTermRef href="CDR0000767747" dictionary="Cancer.gov" audience="Patient">nivolumab</GlossaryTermRef> as the first therapy or alone. This use is approved for the Cabometyx brand of cabozantinib-s-malate.</ListItem></ItemizedList>
  <Para id="_4">Cabozantinib-s-malate
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Cabozantinib-S-Malate</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/461103">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_16.32">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a613015.html">Cabozantinib-S-Malate (for thyroid cancer)</ExternalRef> and <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a616037.html">Cabozantinib-S-Malate (for renal cell carcinoma)</ExternalRef> - Lay language summaries of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_17.33"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_18.34">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/new-nci-precision-medicine-trials">What Comes after NCI-MATCH? NCIâ€™s New Precision Medicine Cancer Trials</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C97938">Find Clinical Trials for Cabozantinib S-malate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2012-12-19</DateFirstPublished><DateLastModified>2025-04-11</DateLastModified></DrugInformationSummary>
